IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Confirmation No.: To be assigned

Jonathan FARBER

Art Unit: To be assigned

Appl. No.: 10/590.155 (U.S. Nat'l Phase Examiner: To be assigned

of PCT/CA2004/001894)

Int'l Filing Date: October 29, 2004 Atty. Docket: 1556.0360002/RWE/S-G

For: Delivery Systems for Calcium

Information Disclosure Statement

Mail Stop Amendment

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

Listed on accompanying IDS Forms are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Copies of documents FP1-FP8 and NPL1-NPL2 are submitted. However, in accordance with 37 C.F.R. § 1.98(a)(2), copies of U.S. patents and patent application publications documents US1-US7 cited on the attached IDS Forms are not submitted.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicant has listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

- 2 -

Jonathan FARBER Appl. No. 10/590,155

Аррі. 140. 10/370,1

over any of the information provided herewith, and/or to prove that this information may

Applicant reserves the right to establish the patentability of the claimed invention

, , , ,

not be prior art, and/or to prove that this information may not be enabling for the

teachings purportedly offered.

This statement should not be construed as a representation that a search has been

made, or that information more material to the examination of the present patent

application does not exist. The Examiner is specifically requested not to rely solely on

the material submitted herewith.

This Information Disclosure Statement is being filed within three months of the

date of filing of a national application other than a continued prosecution application

(CPA). No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the

enclosed IDS Forms, and indicate in the official file wrapper of this patent application

that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee

deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Robert W. Esmond

Attorney for Applicant Registration No. 32,893

Date: October 11, 2006 1100 New York Avenue, N.W. Washington, D.C. 20005-3934

(202) 371-2600

586143_1.DOC

IAP15 Rec'd PCT/PTO 12 OCT 2006

PTO-1390 (Rev. 07-2005)

Approved for use through 3/31/2007. OMB 0851-0021
U.S. Petent end Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays e valid OMB control number.

... 9 ---

	ANSMITTAL LETTER TO	ATTORNEY'S DOCKET NUMBER 1556.0360002/RWE/S-G								
	DESIGNATED/ELECTED ICERNING A SUBMISSIC		U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 10/590,155							
	INTERNATIONAL APPLICATION NO. PCT/CA2004/001894 INTERNATIONAL FILING DATE 29 October 2004 PRIORITY DATE CLAIMED 19 February 2004									
Deliver	TITLE OF INVENTION Delivery Systems for Calcium									
	APPLICANT(S) FOR DOJEO/US Jonathan FARBER									
Applican	t herewith submits to the United Sta	ates Designated/Elected Office (DO/EC	O/US) the following items and other information:							
1.	This is a FIRST submission of items co	ncerning a submission under 35 U.S.C. 371	l.							
2. X	This is a SECOND or SUBSEQUENT s	ubmission of items concerning a submission	n under 35 U.S.C. 371.							
3	This is an express request to begin nati (5), (6), (9) and (21) indicated below.	onal examination procedures (35 U.S.C. 37	1(f)). The submission must include items							
_	The US has been elected (Article 31).									
5	A copy of the International Application									
		only if not communicated by the Internation	nal Bureau).							
	b. has been communicated by									
		cation was filed in the United States Receivi								
6. 🗀		e International Application as filed (35 U.S.C	C. 371(c)(2)).							
	a. is attached hereto.									
. \Box		tted under 35 U.S.C. 154(d)(4).	25.11.0.0.074(-)(0))							
7.	. \square	mational Application under PCT Article 19 (red only if not communicated by the Internal								
		by the International Bureau.	ional Bureau).							
		ever, the time limit for making such amendn	nents has NOT expired							
	d. have not been made and v		iono nas vio y ospitos.							
8. 🔲	An English language translation of th	e amendments to the claims under PCT Art	ticle 19 (35 U.S.C. 371(c)(3)).							
9.	An oath or declaration of the inventor	(s) (35 U.S.C. 371(c)(4)).								
10.	An English language translation of the Article 36 (35 U.S.C. 371(c)(5)).	annexes of the International Preliminary E	xamination Report under PCT							
Items	11 to 20 below concern document(s) or information included:								
11. X	An Information Disclosure Statement	under 37 CFR 1.97 and 1.98.								
12. 🔲	An assignment document for recording	g. A separate cover sheet in compliance wi	th 37 CFR 3.28 and 3.31 is included.							
13.	A preliminary amendment.									
14. 📙	An Application Data Sheet under 37 C	CFR 1.76.								
15.	A substitute specification.									
16.	A power of attorney and/or change of	address letter.								
17.	A computer-readable form of the sequ	ence listing in accordance with PCT Rule 1	3ter.2 and 37 CFR 1.821- 1.825.							
18. 📙	A second copy of the published Intern	ational Application under 35 U.S.C. 154(d)(4).							
19. 🔲	A second copy of the English languag	e translation of the international application	under 35 U.S.C. 154(d)(4).							

This collection of information is required by 37 CFR 1.414 and 1.491-1.492. The information is required to obtain or retain a benefit by the public, which is to file (end by the USPTO) to process) en epigeinstein. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 15 minutes to completed from the USPTO. Time will vary depending upon the individual scale. Any comments on the emount of sine you require to complete tis form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Petent end Tradenat Office. U.S. Dependent Office U.S. 253-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Mail Sup PCT, Commissioner for Petents, P.O. Box 1450, Alexandria, VA 22313-1450. Page 1 of 3

PTO-1390 (Rev. 07-2005)
Approved for use through 3/31/2007, OAM 064-150-150
Approved for use through 3/31/2007, OAM 064-150-150
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent And Trademark Office; U.S. DEPARTMENT OF COMME

U.S. APPLICAT	TION NO. (if known	ATTORNEY'S DOCKET NUMBER				
1	10/590,155 PCT/CA2004/001894				1556.0360002	/RWE/S-G
Listing of the cite A copy of the cite Listing of the cite	items or informati d documents on I d documents FPI d documents on I d documents NPI	Form PTO/SB/08 1 - FPL5 on For Form PTO/SB/08	iA (1 sheet) m PTO/SB/08A iB (1 sheet) Form PTO/SB/08B			
The fell	lowing fees have b	non euhmittad			CALCULATIONS	PTO USE ONLY
				\$300	\$	
22. Exan	nination fee (37 Cl	FR 1.492(c))				
by IPEA/	US indicates all cl	laims satisfy prov	rnational preliminary examina risions of PCT Article 33(1)-(4)	\$0	s	
If the written opin IPEA/US Search fee (37 C International Sea previously	indicates all clain FR 1.445(a)(2)) honal Searching Au irch Report prepar y communicated to	or the Internation as satisfy provision as been paid on athority ted by an ISA oth to the US by the II	nal preliminary examination re ons of PCT Article 33(1)-(4) the international application to er than the US and provided to		\$	
	TOTAL OF 21, 2					
Additional fe sequence electronic	e for specification e listing in complia c medium) (37 CF	and drawings file ince with 37 CFF R 1.492(j)).	ed in paper over 100 sheets (e R 1.821(c) or (e) or computer p s of paper or fraction thereof.			
Total Sheets	Extra Sheets		additional 50 or fraction up to a whole number)	RATE		
- 100 =	/50 =			× \$250	s	1
			ch fee, examination fee, or the ge (37 CFR 1.492(h)).	oath or declaration	s	
CLAIMS	NUMB	ER FILED	NUMBER EXTRA	RATE	\$	
Total claims		- 20 =		× \$50	\$	
Independent clair	ms	- 3 =		x \$200	s	
MULTIPLE DEPE	NDENT CLAIM(S) (if applicable)		+ \$360	s	
			TOTAL OF ABOVE	CALCULATIONS =	\$	
Applicant cla	ims small entity st	atus. See 37 CF	R 1.27. Fees above are reduc	ped by 1/2.		
				SUBTOTAL =	s	
	f \$130.00 for furnis ate (37 CFR 1.492		translation later than 30 mon	ths from the earliest	s	
			TOTAL	NATIONAL FEE =	s 0.00)
Fee for recording by an appropriate	the enclosed ass cover sheet (37 (Ignment (37 CFR CFR 3.28, 3.31).	1.21(h)). The assignment mu \$40.00 per property		s	
			TOTAL F	EES ENCLOSED =	\$ 0.00)
					Amount to be refunded:	s
					Amount to be charged	\$

PTO-1390 (Rev. 07-2005)
Approved for use through 33112007. OMB 0651-0021
U.S. Patient and Trademank Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a

		-
a. 🔲	A check in the amount of \$	to cover the above fees is enclosed.
ь. 🔲	Please charge my Deposit Account No A duplicate copy of this sheet is enclosed.	in the amount of \$ to cover the above fees.
c. X	The Commissioner is hereby authorized to charge any Account No. <u>19-0036</u> . A duplicate copy of this sh	additional fees which may be required, or credit any overpayment to Deposit leet is enclosed.
d. X	Fees are to be charged to a credit card. WARNING: In be included on this form. Provide credit card information	nformation on this form may become public. Credit card information should not ation and authorization on PTO-2038.
	Where an appropriate time limit under 37 CFR 1.495 nted to restore the International Application to pend	has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed ting status.
SEND AL	LL CORRESPONDENCE TO:	Pobutw. Comon
CUS	STOMER NUMBER 26111	SIGNATURE Robert W. Esmond
COB	A CAMER MONIBER 20111	NAME
		32,893
		REGISTRATION NUMBER

-- 1

Equivalent of Form PTO/SB/08A (07-06) Approved for use through 09/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute	for forn		то	Complete if Known		
				Application Number	10/590,155 (U.S. Nat'l Phase of PCT/CA2004/001894)	
INFORMATION DISCLOSURE				Int'l Filing Date	October 29, 2004	
STATEMENT BY APPLICANT				First Named Inventor	Jonathan FARBER	
(Use as many sheets as necessary)				Art Unit	To be assigned	
				Examiner Name	To be assigned	
Sheet	1	of	1	Attorney Docket Number	1556.0360002/RWE/S-G	

			U.S. PATENT DO	CUMENTS		
Examiner Initials	Cite No.1	Document Number Number-Kind Code ^{2 (If Known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appea	
	US1	4,597,981	07-01-1986	Kastin	G Keievant Figures Appea	
	US2	5,928,664	07-27-1999	Yang, et al.		
	US3	6,077,557	06-20-2000	Gordon, et al.	 	
	US4	7,067,150	06-27-2006	Farber, et al.		
	US5	2004/0013732 A1	01-22-2004	Farber, et al.	-	
	US6	2004/0052852 A1	03-18-2004	Farber, et al.		
	US7	2005/0208141 A1	09-22-2005	Farber, et al.		
		2003/0200717110				
- 1			1			

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document			
		Country Code' Number* Kind Code* (if known)			76		
	FPI	UK 691,782	05-20-1953	Chivers & Sons Limited			
	FP2	WO 99/26491	06-03-1999	Bristol-Myers Squibb Company			
	FP3	EP 0 966 208 B1	12-29-1999	Bristol-Myers Squibb Company			
	FP4	WO 01/76610 A1	10-18-2001	Slovakofarma A.S.			
	FP5	WO 03/026438 A1	04-03-2003	Vitalstate Canada, Ltd.			
	FP6	WO 03/026439 A1	04-03-2003	Vitalstate Canada, Ltd.			
	FP7	WO 03/088755 A1	10-30-2003	Vitalstate Canada, Ltd.			
	FP8	WO 05/094782 A1	10-13-2005	Scepter Holdings, Inc.			

586129_1.DOC

•			
ı	Examiner	Date	
ı	0'	Date	
1	Signature	Considered	
L	J	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of his form with next communication to applicant! Applicant's unique citation designation number (options). See Kinds Codes of USPT0 Documents at www.usplo.gov or MPEP 801.04. Enter Office that issued the document, by the Whoteler code (WPPO Standard ST.3). *For Japanese unique proceder his serial number of the patient document with the conformation of the Very Standard ST.30. *For Japanese unique proceder his serial number of the patient document. *Kind of document by the approximation of the Very Standard ST.30. *For Standard ST.30.

document by the appropriate symbols as indicated on the document when it is considered in the public which is to file (and English language Translation is attached, 37 GFR. 1, 37 and 1.88. The information is required to detain or makin a benefit by the public which is to file (and the ordered of information is required by 37 GFR. 1, 37 and 1.88. It is considered by 38 U.S.C. 123 and 37 GFR. 1, 4. This collection is estimated to the lack 2 hours to complete, including opinion and information of the complete the lack of the lac

Approved for use through 09/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO				Con	nplete if Known
				Application Number	10/590,155 (U.S. Nat'l Phase of PCT/CA2004/001894)
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Int'l Filing Date	October 29, 2004
				First Named Inventor	Jonathan FARBER
	(Use as many sheets as necessary)			Art Unit	To be assigned
				Examiner Name	To be assigned
Sheet	1	of	1	Attorney Docket Number	1556.0360002/RWE/S-G

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTRES), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	NPL1	Bell, V.L., et al., "Gelatin-Free Marshmallows," Research Disclosure April 1993:274-275.	
	NPL2	deMan, John M., "Water" and "Additives," in <i>Principles of Food Chemistery:</i> Second Edition, Kluwer Academic Publishers, Norwell, MA., pp.25-26 and 447-448 (1989).	
	NPL3		
	NPL4		
324	NPL5		
	NPL6		
	NPL7		
	NPL8		
	NPL9		
	NPL10		

586134_1.DOC

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and

^{*}EXAMINER: Initial if reference considered, whether or not clastion is in conformance with MFEP 609. Draw line through clation if not in conformance and considered, include copy of this form with next communication to applicant.

Applicant is unjuse citation designation number (optional). *Applicant is to place a check mark here it English language Transistion is statened.

Applicant is unjuse citation designation number (optional). *Applicant is to place a check mark here it English language Transistion is attached by the USF of the Communication o